Skip to content
value.today
Polpharma logo

Polpharma

Unlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
6,250
As of 2018
Wikidata

Polpharma in brief

Polpharma is an unlisted company in the Healthcare sector, based in Starogard Gdański, Poland. It was founded in 1935. It employs about 6,250 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Polpharma

Zakłady Farmaceutyczne Polpharma S.A. ("Pharmaceutical Works Polpharma"), commonly known as Polpharma, is a Polish pharmaceutical company headquartered in Starogard Gdański. It is the largest Polish manufacturer of medicines and active pharmaceutical ingredients (APIs) and the leader of the Polish pharmaceutical market in terms of both volume and value of sales. The company is the parent entity of the Polpharma Group, which operates in Western Europe (including through Farmaprojects in Spain and 089 Pharm in Germany), Central and Eastern Europe and Central Asia, with the group's management headquartered in Warsaw. The group manufactures around 400 million packs of medicines annually, sold in more than 40 countries. In 2025 the company generated sales revenue of PLN 4.93 billion and a net profit of PLN 946 million. The group is owned by Jerzy Starak. Since 1 January 2026 the president (CEO) of the Polpharma Group has been Sebastian Szymanek, who has also served as president of the management board of Zakłady Farmaceutyczne Polpharma S.A. since 2021.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Polpharma timeline

1 events, 1935
  1. 1935
  2. 🏁
    · approximate
    Founded

Events of Polpharma from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Polpharma scorecard#

Passes 1 of the 1 checks that could be worked out. Fiscal year 2018.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 1
    • ✓Profitable in the newest year$118 MNet income $118 M in fiscal 2018.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (wikidata), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

CompanyMarket capP/ENet marginRev. growth
Polpharma🇵🇱————
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Employees:
As of 2018
Profile updated:
Nov 5, 2026

Figures from Wikidata, Wikipedia, Wikimedia Commons, value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Polpharma? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Polpharma's ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Polpharma? Suggest a correction